SPECIAL AUTHORIZATION REQUEST

ULCERATIVE COLITIS

Fax requests to (902) 368-4905 OR email to drugprograms@gov.pe.ca.
HIGH COST DRUG PROGRAM PATIENT APPLICATION ALSO REQUIRED PRIOR TO COVERAGE

Incomplete forms will be returned for completion. If a mailing address and fax number are not provided, we will be unable to issue a response. Approvals will not be considered at doses or dosing intervals outside of PEI guidelines.

SECTION 1 – PRESCRIBER INFORMATION

NAME AND MAILING ADDRESS	
PHONE NUMBER (INCLUDE AREA CODE):	
FAX NUMBER (INCLUDE AREA CODE):	

SECTION 2 – PATIENT INFORMATION

PATIENT (FAMILY NAME)	PATIENT (GIVEN NAME)
DATE OF BIRTH (YYYY/MM/DD)	PERSONAL HEALTH NUMBER (PHN)
PATIENT'S MAILING ADDRESS	

SECTION 3 – MEDICATION, DOSE & COVERAGE CRITERIA

- ☐ **Adalimumab*** – Initial 8 week approval is for an induction dose of 160 mg followed by 80 mg 2 weeks later, then 40 mg every 2 weeks thereafter.
- ☐ **Eltrasimod** – Initial 12 week approval for a maximum dose of 2mg daily.
- ☐ **Infliximab*** – Initial approval is for 3 doses of 5 mg/kg/dose administered at 0, 2 and 6 weeks.
- ☐ **Mirikizumab** – Initial approval is for 300 mg IV at at weeks 0, 4 and 8. If patients do not have adequate therapeutic response at Week 12, 300mg will be reimbursed at weeks 12, 16 and 20
- ☐ **Tofacitinib** – Initial 16 week approval is for a maximum dose of 10 mg twice daily.
- ☐ **Upadacitinib –** Initial 12 week approval is for 45 mg daily for 8 weeks, followed by a maximum of 30 mg daily thereafter.
- ☐ **Ustekinumab*** – Initial 16 week approval is for a single IV dose of up to 520 mg at week 0 and a subcutaneous dose of 90 mg at week 8 and 16
- ☐ **Vedolizumab** – Initial approval is for 300 mg administered at 0, 2 and 6 weeks.

*** Approved requests will be for a biosimilar product**

MODERATE TO SEVERE ULCERATIVE COLITIS CRITERIA - CHECK/FILL OUT RELEVANT BOXES BELOW

☐ **Patient has moderate to severe active Ulcerative Colitis with a partial Mayo score >4 and a rectal bleeding subscore ≥ 2**

AND

☐ **Patient is refractory or intolerant to 5-ASA products (minimum trial of 4 weeks)**

DRUG	DOSE	DURATION OF TREATMENT
If intolerant please explain:		

AND

☐ **Patient has not responded to or intolerant to prednisone 40mg > 2 weeks or IV equivalent > 1 week**

DRUG	DOSE	DURATION OF TREATMENT
If intolerant please explain:		

OR

☐ **Patient is corticosteroid dependent**

Choose one:	Please explain:
☐ Cannot be tapered without disease recurrence **OR**	
☐ Have relapsed within 3 months of stopping treatment **OR**	
☐ Require 2 or more courses within 1 year	

SECTION 4 – CONTINUED COVERAGE

Coverage will be for a maximum of 12 months, except for **biosimilars***, which will be set up for long term coverage.

- ☐ **Adalimumab*** continued coverage will be limited to 40 mg every 2 weeks
- ☐ **Eltrasimod** continued coverage will be limited to 2mg daily
- ☐ **Infliximab*** continued coverage will be limited to 5 mg/kg/dose every 8 weeks
- ☐ **Mirikizumab** continued coverage will be limited to 200 mg every 4 weeks
- ☐ **Tofacitinib** continued coverage will be limited to 10 mg twice daily
- ☐ **Upadacitinib** continued coverage will be limited to 30 mg daily
- ☐ **Ustekinumab*** continued coverage will be limited to 90 mg subcutaneously every 8 weeks
- ☐ **Vedolizumab** continued coverage will be limited to 300 mg every 8 weeks

RENEWAL CRITERIA:

☐ Decrease in the partial Mayo score of at least 2 points from **baseline:** _____

Most recent: _____

AND

☐ Decrease in rectal bleeding subscore of at least 1 point from **baseline:** _____

Most recent: _____

Special Authorization grants coverage to a drug that otherwise would not be eligible for coverage. Coverage is provided to patients in specific medical circumstances as defined in the PEI Pharmacare Formulary and **subject to Pharmacare Drug Program plan rules, including deductible and eligibility requirements.**

PEI Pharmacare may request additional documentation to support this Special Authorization Request. Personal information on this form is collected under section 31(c) of Prince Edward Island's Freedom of Information & Protection of Privacy (FOIPP) Act as it relates directly to and is necessary for providing services under the PEI High-Cost Drug Program. If you have any questions about this collection of personal information, you may contact the program office at 902-368-4947.

PRESCRIBER SIGNATURE (REQUIRED) **DATE**